Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Nevirapine (Viramune®) prolonged release tablets are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults, adolescents, and children three years and above and able to swallow tablets. Prolonged release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate release tablets or oral suspension should be used. Most of the experience with Viramune® is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune® should be based on clinical experience and resistance testing. |
|||
|
|||
Medicine details |
|||
| Medicine name | nevirapine (Viramune®) | ||
| Formulation | 50 mg prolonged-release tablet, 100 mg prolonged-release tablet, 400 mg prolonged-release tablet | ||
| Reference number | 1581 | ||
| Indication | In combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adolescents and children three years and above and able to swallow tablets. Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used. Most of the experience with Viramune is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing |
||
| Company | Boehringer Ingelheim Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1612 | ||
| NMG meeting date | 15/05/2012 | ||
| AWMSG meeting date | 20/06/2012 | ||
| Ratification by Welsh Government | 23/07/2012 | ||
| Date of issue | 27/07/2012 | ||
| Date of last review | December 2022 | ||
| Further information This appraisal recommendation was reviewed in December 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||